Clinical trials are collecting more data than ever before.

Across therapeutic areas, protocols have grown denser: more endpoints, more exploratory analyses, more biomarker sampling, more patient-reported outcomes, more frequent assessments. In many Phase II and III studies, the total number of data points now reaches into the millions.

The question is no longer whether we can collect this volume of data. It’s whether we should.

A growing body of industry research suggests that a meaningful portion of procedures performed in clinical trials fall into categories that are not directly tied to primary or key secondary endpoints. Some are exploratory. Others are legacy elements carried forward from prior studies. Still others are what some teams describe as “non-essential” — procedures that may be scientifically relevant but are performed more frequently than necessary.

Distinguishing between non-core and non-essential data is becoming a critical design discipline.

What’s Core — and What Isn’t?

Core procedures are those directly required to support primary and key secondary endpoints, patient safety monitoring, or regulatory obligations. These are foundational to the trial’s scientific objectives.

Non-core procedures often support exploratory or supplementary objectives. They may be valuable — for hypothesis generation, future analyses, or competitive positioning, but they are not central to the primary question the trial is designed to answer.

Non-essential procedures sit in a different category. These are core procedures that may be conducted more often than required, generating incremental data but also incremental burden.

Individually, each addition can seem minor. Collectively, they reshape the experience of participating in and executing a trial.

The Compounding Effect of “Just One More”

Protocol complexity rarely explodes all at once. It accumulates.

A few extra blood draws to future-proof biomarker analysis. An additional patient-reported outcome instrument to capture quality of life nuances. More frequent safety labs to err on the side of caution. A longer screening window to ensure clean baseline measurements.

Each decision has rationale. But each also adds time, coordination, and effort for patients and sites.

Long screening visits increase screen failure fatigue. Repeated invasive procedures discourage retention. Heavy PRO schedules lead to incomplete data and frustrated participants. Sites, already managing multiple protocols, absorb administrative and data entry burden that compounds across studies.

Importantly, increased data volume does not automatically translate to increased insight. In many cases, the majority of exploratory data is never fully analyzed or included in final reports.

When Data Volume Outpaces Value

Modern trials can generate staggering quantities of data. But without disciplined prioritization, more data can create more noise.

High data volume increases:

• Site workload, through documentation, reconciliation, and query resolution.

• Monitoring burden, as larger datasets require more review cycles.

• Patient fatigue, particularly when assessments are repetitive or time-intensive.

• Cost, through lab processing, logistics, and downstream data management.

It can also introduce risk. More procedures increase the chance of protocol deviations. More endpoints increase the risk of multiplicity challenges and interpretability issues.

Rethinking data collection is not about lowering scientific standards. It is about aligning data with purpose.

A Fit-for-Purpose Data Mindset

A more deliberate approach begins with a simple but powerful question:

What decision will this data inform?

If the answer is unclear, or if the decision is unlikely to influence the current program, the value of collecting that data should be scrutinized.

Forward-looking organizations are increasingly applying structured frameworks during protocol development to categorize procedures by purpose and impact. These reviews assess:

• Direct linkage to primary or key secondary endpoints.

• Regulatory requirements.

• Contribution to safety monitoring.

• Incremental value versus incremental burden.

• Frequency appropriateness.

These conversations are most effective when held early, before protocol finalization, and when they include cross-functional perspectives; clinical, biostatistics, operations, patient engagement, and site insights.

When teams quantify the time required per visit, total blood volume, cumulative PRO minutes, and overall screening duration, trade-offs become visible. Decisions shift from habit to intention.

Data Discipline as a Competitive Advantage

In an environment where enrollment timelines are tight and site capacity is strained, disciplined data collection can become a differentiator.

Trials designed with focused, essential data strategies often see:

• Shorter visit durations.

• Reduced screen failure rates.

• Improved retention.

• Lower amendment frequency.

• Greater operational predictability.

Importantly, reducing non-core and non-essential procedures does not diminish innovation. It creates space for smarter innovation, targeted exploratory analyses, digital biomarkers, or real-world integrations that are clearly aligned with study objectives.

The goal is not minimalism. It is precision.

Designing for Insight, Not Volume

As the industry continues to embrace digital tools, structured protocols, and AI-enabled analytics, the ability to collect data will only expand. The constraint will not be technology — it will be judgment.

The most effective trials of the next decade will not be defined by how much data they gather, but by how thoughtfully that data is selected.

In a world of millions of data points, clarity of purpose is the real competitive edge.

Continue the Conversation at SCOPE X

If you’re exploring how AI, structured protocol data, and advanced analytics can help teams design smarter, more focused trials, join us at SCOPE X, a dedicated event focused on AI innovation in clinical research.

SCOPE X brings together clinical, data, and technology leaders to examine practical strategies for optimizing protocol design, improving feasibility, reducing burden, and applying AI responsibly across the trial lifecycle.

Learn more at:
https://www.scopesummit.com/scopex

Because better trials aren’t built by collecting more data. They’re built by collecting the right data.